Navigation Links
US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
Date:8/16/2009

hese risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, preventive vaccines, diagnostic tools, cost-saving generic pharmaceuticals, and consumer health products. Novartis is the only company with leading positions in these areas. In 2008, the Group's continuing operations achieved net sales of USD 41.5 billion and net income of USD 8.2 billion. Approximately USD 7.2 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 99,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

References

    '/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
2. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
3. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
4. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
5. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
6. FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
7. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
8. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
9. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
10. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
11. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... announced registered offering of common shares in ... the Offering, the Company issued 7,286,432 common shares at ... proceeds of approximately $1.45 billion. On March 18, 2015, ... Commission a final prospectus supplement to its effective shelf ...
(Date:3/27/2015)... , March 27, 2015 As ... shipments of incontinence devices for women. ... the most gratifying part is the hundreds of ... women whose lives have been positively impacted by ... of InControl. InControl recently released Apex, ...
(Date:3/27/2015)... 2015   Hospira, Inc. (NYSE: ... the world,s leading provider of injectable drugs and ... evaluation of biosimilarity of its proposed biosimilar, Epoetin ... (FDA) conditionally approved name of RETACRIT™, compared to ... study data were presented at the National Kidney ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... Primary Endpoint of the Trial to Be Clarified ... Arbios Systems, Inc.,(OTC Bulletin Board: ABOS) announced today ... U.S. Food and Drug Administration ("FDA") of,an Investigational ... for SEPET(TM), Arbios, extracorporeal (outside the body) artificial,liver ...
... Feb. 21 Accumetrics, Inc. a privately-held,medical device ... tests that,measure patient response to antiplatelet drugs, announced ... Series D financing. The syndicate was led by,Arnerich ... Also participating,in the round were previous investors: Essex ...
Cached Medicine Technology:Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 2Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 3Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM) 4Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial 2
(Date:3/28/2015)... March 28, 2015 "Necrorun" was featured ... takes a look at the latest and coolest applications ... Troohey, the host of NewsWatch and technology expert, conducted ... is an entertaining endless runner game with knights, nature, ... was released in 2009, according to Eurogamer. The popularity ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 With ... in the fields of osteoporosis, osteoarthritis and musculoskeletal ... Osteoporosis, it may be the first time in ... research forum that the hot-button topic is an ... on the well-accepted scientific principles of Wolff’s law, ...
(Date:3/28/2015)... March 28, 2015 The California-based leading ... for every customer shopping on UniWigs during the Easter ... be a big promotion on April Fools’ Day. , ... is just around the corner. Easter Festival, with religious ... is a major holiday after Christmas. The best wig ...
(Date:3/28/2015)... FL (PRWEB) March 28, 2015 ... conditions coverage is made available to all visitors who ... effective immediately. All members are encouraged to purchase the ... to avoid lack of proper coverage for pre-existing medical ... from one or two medical conditions with serious consequences ...
(Date:3/28/2015)... 28, 2015 Centurion Service Group will be ... Thursday, April 2 at their Las Vegas warehouse, located at ... The sale, which consists of equipment from hospitals and surgery ... 9 a.m. PDT. , Buyers will find items of ... “We are a one-stop-shop,” said Erik Tivin, CEO of Centurion. ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Medical Equipment Auction to Take Place in North Las Vegas 2
... no proof the procedures work and serious side effects ... News) -- Claims by spas that "lipodissolve" injections can ... also remains in question, according to warning letters issued ... The FDA warned six U.S. based medical spas and ...
... iron to Alzheimer,s disease, heart disease, and other age-related disorders, ... suggests specific steps that older consumers can take to ... their bodies. "This story of copper and iron toxicity, which ... is virtually unknown to the general medical community, to say ...
... ... announced today that it has appointed Mick Simon to serve as Executive Vice President ... Business Intelligence Solutions and personal health management clinical services to self insured employers, other ... , ...
... Adherence to treatment declines if adults fail to monitor, ... Children and teens with type 1 diabetes are less ... parents become lax about monitoring their treatment or if ... found. , Failure to properly manage type 1 diabetes, ...
... hooking up takes over from dating as a means of ... to prefer dating whereas more men than women rate hooking ... risks to dating and hooking up. Carolyn Bradshaw from James ... that motivate college men and women to hook up or ...
... this as troubling individually and for society , WEDNESDAY, ... mobility are increasing among middle-age Americans, a new study ... long-term consequences for the U.S. health-care system. , Researchers ... data from the annual National Health Interview Survey, covering ...
Cached Medicine News:Health News:FDA Issues Warning on 'Fat-Melting' Spa Injections 2Health News:HCMS Group LLC Names Mick Simon Chief Operating Officer 2Health News:Kids Need Parents' Help in Managing Type 1 Diabetes 2Health News:Hooking up or dating: Who benefits? 2Health News:Middle-Age Americans Less Mobile Than Ever 2
Silicone Foley Catheters 2-Way (Pediatric)...
Midstream Catch Kits...
Midstream Catch Kits...
... The Pediatric BladderScan® is ... Diagnostic Ultrasound's trusted family ... enabling healthcare providers to ... volume noninvasively, this easy-to-use, ...
Medicine Products: